News | August 08, 2007

CAD Marks 96 Percent of Cancers Detected with FFDM

August 9, 2007 - Hologic Inc. announced that, according to a recent independent peer-reviewed study published in the July issue of Radiology, computer aided detection correctly marked 99 (96.1 percent) of 103 consecutive asymptomatic breast cancers detected with digital mammographic screening, with an acceptable false marker rate (1.80 false CAD marks per patient). The CAD system (ImageChecker M1000 version 3.1) used in this study was from Hologic’s R2 Technology subsidiary.

Yang and co workers, from the Seoul National University Medical Research Center, reported that the R2 CAD system “marked all 44 breast cancers that manifested as microcalcifications only, all 23 breast cancers that manifested as a mass with microcalcifications and 32 (89 percent) of 36 lesions that appeared as a mass only.” “We are pleased that this study (the first to be published on R2 digital CAD by an independent medical facility) showed such strong results. Of particular note, CAD correctly marked the single invasive lobular carcinoma lesion and 67 of 71 (94.4 percent) of invasive ductal carcinomas, of which 22 had a component of DCIS. As digital mammography gains wider acceptance, R2’s CAD will continue to be a valuable tool to assist radiologists in the earlier detection of breast cancer”, said Dr. Ronald A. Castellino, R2 Technology’s chief medical officer.

Hologic|R2 continues to develop and refine it’s CAD solutions and is currently marketing ImageChecker V8.3 for digital mammography.

For more information: www.r2tech.com and www.hologic.com

Related Content

MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
iCAD Announces Positive Clinical Results for Artificial Intelligence Tomosynthesis Technology
News | Mammography | October 11, 2018
iCAD Inc. announced positive clinical results of its new digital breast tomosynthesis (DBT) cancer detection software,...
SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Riverain Technologies Issued U.S. Patent for Vessel Suppression Technology
News | Computed Tomography (CT) | June 14, 2018
Riverain Technologies announced that the United States Patent and Trademark Office (USPTO) has awarded the company a...
FDA Issues Proposed Order to Reclassify Certain Radiological Medical Image Analyzers
News | Computer-Aided Detection Software | June 01, 2018
The U.S. Food and Drug Administration (FDA) is issuing a proposed order to reclassify certain radiological medical...
Median Technologies and the Nice University Hospital to Use AI in Lung Cancer Screening
News | Artificial Intelligence | March 15, 2018
March 15, 2018 – Median Technologies, the industry-leading Imaging Phenomics Company and the Nice University Hospital
FDA Clears First AI-Powered Clinical Decision Support Software for Stroke
Technology | Clinical Decision Support | February 14, 2018
The U.S. Food and Drug Administration (FDA) announced marketing clearance for Viz.AI’s Contact application, the first ...
Transpara Deep Learning Software Matches Experienced Radiologists in Mammogram Reading
News | Computer-Aided Detection Software | January 12, 2018
Deep learning and artificial intelligence improves the efficiency and accuracy of reading mammograms, according to...